Alport Syndrome - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Alport Syndrome Emerging Therapy and TPP Insights

Thelansis's "Alport Syndrome Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Alport Syndrome Overview

Alport syndrome is a rare, progressive hereditary disorder of basement membranes caused by pathogenic mutations in the COL4A3, COL4A4, or COL4A5 genes, which encode the alpha-3, alpha-4, and alpha-5 chains of type IV collagen. The disease most commonly follows an X-linked inheritance pattern, leading to structural defects in the glomerular basement membrane (GBM), cochlea, and ocular tissues.

This disruption of the collagen network results in a characteristic clinical triad of progressive sensorineural hearing loss, ocular abnormalities (notably anterior lenticonus), and hematuric nephropathy. The renal disease progresses from microhematuria and proteinuria to end-stage renal disease (ESRD) over time.

Diagnosis has shifted toward molecular genetic testing, replacing traditional renal biopsy findings such as GBM lamellation and "basket-weave" splitting. Currently, there are no therapies that correct the underlying genetic defect, and management focuses on early nephroprotection, primarily through RAAS blockade (ACE inhibitors/ARBs), with increasing use of SGLT2 inhibitors to delay renal progression. Emerging therapies targeting fibrosis and endothelin pathways are under investigation.

Key Highlights

• Alport syndrome is a rare, progressive genetic renal disorder with multisystem involvement
• France prevalence expected to increase from 9.8K to 12.3K (~2.3% CAGR)

Market Overview

• France market projected to grow from $1.7M to $2.3M (~3% CAGR)
• Growth remains limited due to lack of disease-modifying therapies, with pipeline innovation driving future potential

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Enyo Pharma
• Calliditas Therapeutics AB
• Eloxx Pharmaceuticals, Inc.
• Biogen
• Bayer
• River 3 Renal Corp.
• Novartis Pharmaceuticals